Mithra Pharmaceuticals
Rue Saint-Georges 5
Liège
4000
Tel: 32-0-4-349-28-22
Fax: 32-0-4-349-28-21
Website: http://www.mithra.com/
Email: info@mithra.com
About Mithra Pharmaceuticals
Mithra is a pharmaceutical company focused on the development, manufacturing and commercialisation of proprietary, innovative and differentiated drugs and complex therapeutical solutions dedicated to female healthcare.YEAR FOUNDED:
1999
LEADERSHIP:
CEO: François Fornieri
CFO: Steven Peters
CCO: Julie Dessart
JOBS:
Please click here for Mithra job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
40 articles about Mithra Pharmaceuticals
-
Mithra updates on cash position - February 06, 2024
2/6/2024
Mithra, a company dedicated to women’s health, provides an update on its current cash position and its plans to address its runway and creating and optimizing value for all its stakeholders.
-
Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel
12/21/2023
Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the signing of a binding Head of Terms (HoT) agreement for the commercialization of DONESTA® in Israel with Rafa Laboratories LTD, an Israeli pharmaceutical company.
-
Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients
12/20/2023
Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the completion of a pediatric study of its marketed contraceptive ESTELLE® in adolescent women.
-
Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States
11/30/2023
Mithra announces that the US Food and Drug Administration has provided feedback regarding its new drug application marketing authorization filing in the United States.
-
Mithra’s NEXTSTELLIS® granted additional patent in the United States
11/7/2023
Mithra, a company dedicated to Women’s Health, announces that it has been granted an additional patent for NEXTSTELLIS® tablets) in the United States.
-
Mithra and Searchlight Pharma Announce Donesta® Licensing Agreement for Canada
7/31/2023
Mithra announced the signing of a binding term sheet for a licensing agreement for the Canadian rights to Donesta®, an investigational medicine for the treatment of the symptoms of menopause.
-
Mithra and Searchlight Pharma Announce Nextstellis Approval in Canada
3/8/2021
First E4-based product approved internationally Canadian regulatory approval is the first in the world for the novel combined oral contraceptive Nextstellis ® Innovative product developed by Mithra containing the unique native estrogen Estetrol (E4) and drospirenone (DRSP) Approval supported by two large multinational Phase 3 studies conducted in 3,725 women
-
Mayne Pharma Signs 20-Year Exclusive License and Supply Agreement for Novel Oral Contraceptive in the US
10/2/2019
Mayne Pharma is pleased to announce it has entered into an exclusive license and supply agreement with Mithra to commercialise E4/DRSP, a combined oral contraceptive, in the United States.
-
Mithra Announces Positive Donesta® Phase Iib Study Achieving Primary Objective and Confirming Promising Safety Profile
4/20/2018
Mithra announces positive topline results from the E4 Relief Phase II study of Donesta® for the treatment of Vasomotor Symptoms (VMS), and in particular hot flushes relief, in post-menopausal women, with the study achieving its primary and key secondary objectives.
-
Mithra Announces Positive Outcome of Myring Commercial Batch Bioequivalence Study
11/17/2017
The study results reconfirm that Myring is bioequivalent to Nuvaring, a combined hormonal contraceptive vaginal ring made of ethylene vinyl acetate copolymers.
-
Mithra Completes Recruitment for Estelle Phase III Study in US & Canada
10/31/2017
Mithra today announces the completion of recruitment in the E4 Freedom Phase III study of Estelle in the US and Canada. Estelle is Mithra’s combined oral contraceptive candidate composed of 15 mg Estetrol (E4) and 3 mg drospirenone.
-
Mithra Announces Completion Of Recruitment In Donesta Phase II Study
10/16/2017
Mithra, a company specialized in Women’s Health, today announces the completion of recruitment in the E4 Relief Phase II study of Donesta.
-
Mithra Pharmaceuticals’s Marketing Authorization Application For Tibelia Accepted By Health Canada
10/10/2017
-
Mithra Pharmaceuticals Announces 2017 Half Year Results
9/21/2017
-
Mithra Pharmaceuticals Announces First Subject Completes Estelle Phase III Study
8/18/2017
-
Mithra Pharmaceuticals Release: Recruitment Completed In Estelle Population Pk Substudy
8/9/2017
-
Mithra Pharmaceuticals Submits Myring For European Marketing Approval
7/17/2017
-
Mithra Pharmaceuticals Strengthens E4 Patent Position In Australian Market
7/6/2017
-
Mithra Pharmaceuticals Signs Exclusive License And Supply Agreement With Fuji Pharmaceutical Co., Ltd. For Donesta In Japan And Asean
6/28/2017
-
Mithra Pharmaceuticals Release: Estelle Phase IIb Results On Well-Being And Body Weight Published In Leading Peer-Reviewed Journal
6/26/2017